Delivering the next generation of rationally designed cancer therapies
SLC Bio combines the power of structure-based drug discovery, with the know-how in context specific cell-based assays, to create novel therapies targeting Solute Carrier Transporters in oncology, expanding treatment options for patients. Our first focus is in acute myeloid leukemia, a blood cancer with high unmet need affecting an aging population.
SLC Bio
advantage
Our focus on SLC transporters will result in first-in-class personalized therapies for hematological malignancies.
Our Bioinformatic approach combined with computation chemistry and target class expertise will lead to rapid developmental candidate selection, eliminating the need for trial-and-error experimental screening of tens of thousands of molecules
While the first focus is on AML, we are building a knowledge base on SLC transporters in oncology and aim to work on other high-value SLC targets amenable to our approach
